MK-8353
Total Payments
$3.3M
Transactions
697
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $967,056 | 141 | 0 |
| 2019 | $1.3M | 182 | 3 |
| 2018 | $805,209 | 155 | 1 |
| 2017 | $292,177 | 219 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.3M | 676 | 99.8% |
| Consulting Fee | $4,153 | 4 | 0.1% |
| Travel and Lodging | $1,136 | 7 | 0.0% |
| Food and Beverage | $350.19 | 10 | 0.0% |
Payments by Type
Research
$3.3M
676 transactions
General
$5,639
21 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in combination with Pembrolizumab in Patients with Advanced Malignancies | Merck Sharp & Dohme Corporation | $2.8M | 0 |
| Phase 1b Open-label Study of MK-8353 in Combination with Selumetinib MK-5618 in Participants with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $478,868 | 0 |
| A Study of MK-8558 Drug-Drug Interaction with MK-8591 and MK-8558 Once Daily Pharmacokinetics | Merck Sharp & Dohme Corporation | $19,880 | 0 |
| A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK8353 formerly known as SCH 900353 in Subjects with Advanced Solid Tumors Protocol No. 001 formerly known as P06203 | Merck Sharp & Dohme Corporation | $18,901 | 0 |
Top Doctors Receiving Payments for MK-8353
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $3.3M | 676 |
| , MD | Endocrinology, Diabetes & Metabolism | Chicago, IL | $3,057 | 3 |
| Anthony Tolcher | Medical Oncology | San Antonio, TX | $763.26 | 7 |
| , M.D | Diagnostic Radiology | Kendall Park, NJ | $675.00 | 2 |
| , MD | Medical Oncology | Sarasota, FL | $656.25 | 8 |
| , MD, MPH | Cardiovascular Disease | Dallas, TX | $487.50 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.3M
- Total Doctors 5
- Transactions 697
About MK-8353
MK-8353 is a drug associated with $3.3M in payments to 5 healthcare providers, recorded across 697 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $967,056 was paid across 141 transactions to 0 doctors.
The most common payment nature for MK-8353 is "Unspecified" ($3.3M, 99.8% of total).
MK-8353 is associated with 4 research studies, including "A Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in combination with Pembrolizumab in Patients with Advanced Malignancies" ($2.8M).